Skip to content
Clinical Trials – home
Not yet recruiting

Low‑dose cyclophosphamide maintenance therapy to prevent recurrence in patients with pancreatic cancer after surgery and neoadjuvant chemotherapy

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial focuses on pancreatic ductal adenocarcinoma (PDAC), a type of cancer that starts in the pancreas. Participants have already undergone a major operation to remove the tumor (called a radical surgical resection) and received chemotherapy before surgery (known as neoadjuvant systemic chemotherapy). After these steps, the study investigates the use of a low‑dose oral medication, Endoxan (cyclophosphamide), given as a maintenance therapy to try to eliminate any tiny cancer cells that may still be present.

The purpose of the study is to compare the length of time without cancer recurrence, called DFS, between patients who receive the low‑dose medication (Arm A) and those who do not receive additional treatment (Arm B). Participants will be followed for several months after starting the maintenance phase, during which they will take the study drug daily and attend regular check‑ups to monitor side effects, overall health, and quality of life. Secondary observations will look at overall survival, patterns of cancer return, side effects, and how patients feel during the study.

The research process

The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Baseline Assessments

    After joining the study, you will undergo a series of baseline assessments to confirm that you meet the study requirements. These assessments may include a review of your medical history, physical examination, blood tests, and imaging studies.

    The purpose of these assessments is to document your health status before starting the maintenance phase of the trial.

  2. Step 2

    Randomization

    Following the baseline assessments, you will be randomly assigned to one of two groups:

    Arm A: Receive low‑dose cyclophosphamide as maintenance therapy.

    Arm B: No additional medication (observation only).

    Randomization ensures that the groups are comparable and that the study can evaluate the effect of the medication.

  3. Step 3

    Start of Maintenance Therapy (Arm A Only)

    If you are assigned to Arm A, you will begin taking the study medication shortly after randomization.

    The medication is a film‑coated tablet containing cyclophosphamide monohydrate.

    You will take one tablet orally each day, providing a dose of 200 mg.

  4. Step 4

    Medication Administration Schedule

    The daily dose of 200 mg cyclophosphamide is taken by mouth with water.

    You should take the tablet at the same time each day to maintain a consistent schedule.

    The medication will be continued for as long as you remain in the study, unless disease recurrence, unacceptable side effects, or a decision by the study team to stop treatment occurs.

  5. Step 5

    Regular Monitoring Visits

    You will attend scheduled clinic visits approximately every 4 to 8 weeks.

    During each visit, the study team will check your blood counts, kidney and liver function, and look for any side effects (known as toxicity).

    Imaging studies may be performed periodically to assess whether the cancer has returned.

  6. Step 6

    Assessment of Disease‑Free Survival (DFS)

    Disease‑free survival (DFS) refers to the length of time after treatment during which no signs of cancer are detected.

    The study will compare DFS between patients who receive cyclophosphamide (Arm A) and those who do not (Arm B).

  7. Step 7

    Assessment of Overall Survival (OS) and Quality of Life (QoL)

    Overall survival (OS) measures the time from the start of the study until death from any cause.

    Your quality of life (QoL) will be evaluated using questionnaires at selected visits to understand how the treatment affects daily living.

  8. Step 8

    End of Treatment

    Treatment with cyclophosphamide will stop if any of the following occur:

    • Disease recurrence is confirmed.

    • Side effects become severe enough to outweigh potential benefit.

    • The study reaches its planned end date.

    After stopping the medication, you will have a final assessment to document your health status.

  9. Step 9

    Long‑Term Follow‑Up

    Even after treatment ends, you will continue to be followed by the study team for several years.

    Follow‑up visits will focus on monitoring for cancer recurrence, overall survival, and any late side effects.

    These visits help the study determine the long‑term impact of low‑dose cyclophosphamide maintenance therapy.

Who can join the trial?

10 criteria

  • Provide written informed consent, which means you agree in writing after understanding the study.
  • Have good liver health: the blood tests called ALT and AST must be less than three times the normal limit, and the total amount of bilirubin in your blood must be 1.5 times the normal limit or lower.
  • Be 18 years of age or older, regardless of gender, race, or ethnicity.
  • Have a confirmed diagnosis of PDAC (a type of pancreatic cancer) based on tissue examination.
  • Have had a previous radical (R0 or R1) surgical resection, which means the tumor was surgically removed with the goal of no cancer left at the edges (R0) or a very small amount left (R1).
  • Have completed neoadjuvant therapy (NAT) using the PAXG regimen for 4 to 6 months, which is chemotherapy given before surgery.
  • Agree to have blood drawn so that plasma and other blood samples can be used for study testing.
  • Have an ECOG performance status of 2 or lower, meaning you are fully active or able to carry out light work but not bedridden.
  • Have adequate bone marrow function, shown by blood counts of: white blood cells (GB) at least 3,500 per mm³, neutrophils at least 1,500 per mm³, platelets at least 100,000 per mm³, and hemoglobin (Hb) at least 10 g/dL.
  • Have good kidney function, with a blood level of creatinine less than 1.5 mg/dL.

Who cannot join the trial?

15 criteria

  • Pregnancy, breastfeeding (lactation), or not using reliable birth control if you could become pregnant – you cannot join the study.
  • Any health problem or lab test result that would put you at high risk if you took part in the study.
  • A condition that would make it hard for researchers to understand the study results.
  • Family, social, or living situations that might stop you from following the study plan or attending follow‑up visits.
  • Inflammatory disease of the colon or rectum, or a blockage (partial or complete) in the intestine.
  • Taking other experimental drugs at the same time as this study.
  • Lactose intolerance when the study site cannot provide a special medication that does not contain lactose.
  • Having other types of pancreatic tumors that are not the usual ductal cancer, such as hormone‑producing tumors, acinar cell cancer, cystic cancer, or cancers near the opening of the pancreas (periampullary malignancies).
  • Having another cancer diagnosed or treated within the past year, except for very early skin cancers or a pre‑cancer of the cervix that was fully removed.
  • Having an active bacterial, viral, or fungal infection that needs treatment and has not gotten better with medication.
  • Taking medicines that suppress the immune system (immunosuppressive) or lower blood cell production (myelosuppressive), which could increase the risk of serious low‑white‑blood‑cell problems.
  • Any sign that the cancer is still present anywhere in the body (evidence of disease).
  • A rise in tumor marker levels (blood tests that can show cancer activity) (tumor marker increase).
  • Serious health problems affecting major organs (like heart, liver, or kidneys) or serious mental health disorders that could endanger you or affect the study data.
  • Any significant medical condition, lab abnormality, or psychiatric illness that would prevent you from participating in the study.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

cyclophosphamide is an oral chemotherapy medicine that is given in low doses after a patient has already received the main chemotherapy and surgery for pancreatic cancer. In this trial, patients take the drug for a period of time to try to kill any tiny cancer cells that might still be left behind, hoping to prevent the cancer from coming back. The study compares how long patients stay free of disease when they receive this low‑dose maintenance treatment versus when they receive no additional medication.

What is already known about the treatment

Cyclophosphamide - It is taken by mouth as a film‑coated tablet, usually 200 mg per dose. Cyclophosphamide is an approved chemotherapy drug that has been used for many years and is well described in medical literature. It is mainly used to treat various cancers, including pancreatic cancer when given after surgery and other chemotherapy. The drug works by entering cells and changing their DNA so they cannot grow or divide, and it belongs to the class of alkylating agents.

Investigated diseases

Pancreatic ductal adenocarcinoma - It is a cancer that begins in the ducts that carry digestive enzymes from the pancreas. The tumor usually grows outward, invading nearby tissues such as the duodenum and blood vessels. Over time cancer cells can spread through the bloodstream to the liver, lungs, and other organs. The disease often advances without obvious symptoms in its early stages, leading to later detection.
Trial detailsLast updated 17 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-526296-28-00Protocol codeLOCH NESS - PACT-35Estimated enrolment238 patientsSponsorAssociazione Italiana Per Lo Studio Del Pancreas

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.